share_log
Reuters ·  May 8 08:02
Acumen Pharmaceuticals Inc: Expects to Initiate a Phase 1 Bioavailability Study to Support a Subcutaneous Dosing Option of Sabirnetug in Mid-2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment